Table 4.
Patients’ secondary outcomes for administration of erythropoietin
| Treated (n = 110) |
Not treated (n = 248) |
P-value | Adjusted OR (95% CI) |
Adjusted P-value |
|
| Male, n (%) | 54 (49) | 139 (56) | 0.22 | 1.22 (0.59-2.53) | 0.59 |
| Gestational age (weeks), median (IQR) | 32.8 (31.6-33.7) | 35.0 (34.1-35.4) | <0.001 | 0.28 (0.18-0.42) | <0.001 |
| SGA, n (%) | 32 (29) | 43 (17) | 0.01 | 3.67 (1.35-9.99) | 0.01 |
| Caesarian section, n (%) | 96 (87) | 173 (70) | <0.001 | 2.36 (0.89-6.27) | 0.09 |
| Twin birth, n (%) | 28 (25) | 56 (23) | 0.55 | 1.73 (0.74-4.07) | 0.21 |
| Placental abruption, n (%) | 5 (4.5) | 9 (3.6) | 0.68 | 1.75 (0.34-8.95) | 0.50 |
| Maternal Hb before birth (g/dL), mean (SD) | 10.8 (1.6) | 11.0 (1.3) | 0.07 | 0.79 (0.62-1.02) | 0.07 |
| Laboratory data at birth | |||||
| Hb (g/dL), mean (SD) | 16.7 (2.2) | 17.0 (2.2) | 0.20 | 0.90 (0.74-1.08) | 0.26 |
| MCV (fL), mean (SD) | 110 (6.7) | 108 (5.7) | 0.01 | 0.92 (0.86-0.98) | 0.01 |
| MCHC (%), mean (SD) | 34.2 (1.1) | 34.2 (1.0) | 0.28 | 1.12 (0.80-1.56) | 0.50 |
| Ret (×104/μL), mean (SD) | 26.4 (7.8) | 24.6 (5.7) | 0.007 | 0.95 (0.90-1.01) | 0.12 |
| High intensity breastfeeding, n (%) | 47 (43) | 56 (23) | <0.001 | 0.65 (0.31-1.35) | 0.25 |
| Treatment for jaundice, n (%) | 93 (85) | 127 (51) | <0.001 | 1.08 (0.41-2.84) | 0.88 |
| Number of blood samplings, median (IQR) | |||||
| Large sampling | 8 (6-10) | 3 (2-5) | <0.001 | 1.42 (1.17-1.73) | <0.001 |
| Small sampling | 14 (10-21) | 9 (7-13) | <0.001 | 0.96 (0.90-1.02) | 0.23 |
| Days at the initiation of treatment (days), mean (SD) | 17.6 (6.8) | ||||
| Hb at the initiation of treatment (g/dL), mean (SD) | 13.0 (1.3) |
SGA, small for gestational age; Hb, hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; Ret, absolute reticulocyte count